Beclomethasone Inhalation

Introduction Overview

Generic Name

beclomethasone inhalation

Brand Name

Qvar Redihaler

Dosage Form

Pressurized metered-dose inhaler (pMDI) with breath-actuated technology

Drug Class

Inhaled corticosteroids

Pharmacokinetics

Absorption:
Beclomethasone dipropionate, the active ingredient in Qvar Redihaler, is administered via inhalation directly to the lungs. The drug is absorbed through the respiratory mucosa, achieving local anti-inflammatory effects. Due to the inhaled route, systemic bioavailability is limited but significant enough to elicit some systemic effects. About 20-40% of the inhaled dose is deposited in the lungs, where it is rapidly hydrolyzed to the active metabolite beclomethasone-17-monopropionate (B17MP). The oropharyngeal deposition leads to some absorption through the gastrointestinal tract, but most of this portion undergoes extensive first-pass metabolism, minimizing systemic availability from this route.

Distribution:
Once absorbed systemically, beclomethasone metabolites demonstrate binding to plasma proteins and distribute moderately into body tissues. The active metabolite B17MP is primarily responsible for the pharmacological effects and has intermediate lipophilicity allowing effective penetration of airway tissues. The volume of distribution is consistent with distribution in extracellular fluids and lung tissues. Beclomethasone and its metabolites have low penetration across the blood-brain barrier.

Metabolism:
Beclomethasone dipropionate is rapidly metabolized by esterases in the lungs and plasma to its active metabolite, beclomethasone-17-monopropionate. This metabolite is the principal agent responsible for glucocorticoid activity. Further metabolism occurs predominantly in the liver via cytochrome P450 enzymes, including CYP3A4 isoenzymes, yielding inactive metabolites. This extensive hepatic metabolism accounts for the drug's low systemic bioavailability and reduced systemic corticosteroid side effects.

Elimination:
The inactive metabolites of beclomethasone are primarily excreted via the kidneys, with minor biliary excretion. The elimination half-life of beclomethasone-17-monopropionate is approximately 2-3 hours. Renal clearance facilitates elimination of metabolites, and no significant accumulation occurs with regular inhaled dosing. Clearance can be affected by hepatic or renal impairment, but inhaled doses typically do not cause systemic toxicity.

Dosage Forms

Available Dosage Forms:
Qvar Redihaler is available as a breath-actuated, pressurized metered-dose inhaler containing beclomethasone dipropionate. The device delivers a consistent dose with each inhalation without the need for coordination of actuation and inhalation.

Dosages for Adults and Adolescents:
Dosing typically begins at 40 to 80 micrograms twice daily for maintenance therapy of asthma in adults and adolescents aged 12 years and older. Depending on asthma severity and response, dosing may be increased gradually with a maximum dose generally up to 320 micrograms twice daily. Dose titration should be individualized based on clinical response and lung function testing.

Specific Patient Populations:
In pediatric patients aged 4 to less than 12 years, initial dosing often starts lower, such as 40 micrograms twice daily, with careful monitoring of efficacy and adverse effects, especially considering potential effects on growth. Elderly patients and those with hepatic or renal impairments generally require no dosage adjustment due to low systemic exposure, but clinical monitoring is recommended. Because systemic corticosteroid side effects may arise with higher dosages or prolonged use, dosing should adhere strictly to efficacy and safety considerations in all populations.

Mechanism Of Action

Beclomethasone dipropionate is an inhaled corticosteroid that exerts potent anti-inflammatory effects primarily through glucocorticoid receptor agonism. Upon inhalation, it deposits in the airway mucosa where it is rapidly converted to the active metabolite beclomethasone-17-monopropionate, which binds to intracellular glucocorticoid receptors. This receptor-ligand complex translocates into the nucleus, modulating the transcription of specific genes involved in inflammatory responses.

At the molecular level, beclomethasone increases the expression of anti-inflammatory proteins such as lipocortin-1 while suppressing pro-inflammatory cytokines including interleukins, tumor necrosis factor-alpha, and other mediators like prostaglandins and leukotrienes. It inhibits the recruitment and activation of inflammatory cells (e.g., eosinophils, mast cells, T-lymphocytes) within the airway mucosa, thereby reducing airway hyperresponsiveness, edema, mucus secretion, and tissue remodeling over time.

Unlike systemic corticosteroids, inhaled beclomethasone targets the local airway inflammation with minimal systemic glucocorticoid exposure, thus reducing systemic adverse effects. Clinically, this action decreases frequency and severity of asthma exacerbations but does not provide immediate bronchodilation. Therefore, Qvar Redihaler is indicated for maintenance therapy to control persistent asthma rather than acute relief.

Compared to other inhaled corticosteroids like fluticasone or budesonide, beclomethasone has similar efficacy but differences exist in pharmacokinetics and particle size distribution, which may influence lung deposition and clinical effect. Clinical studies have demonstrated that regular use improves pulmonary function tests and asthma symptoms while lowering need for systemic corticosteroids.

Pharmacological Actions

Inhaled corticosteroid with potent local anti-inflammatory effects on the respiratory tract.
Suppresses airway inflammation by modulating cytokine production and inflammatory cell activity.
Reduces airway hyperresponsiveness and mucus hypersecretion associated with asthma.
Inhibits release of arachidonic acid metabolites, decreasing prostaglandin and leukotriene synthesis.
Decreases eosinophil influx and activation in the airway mucosa.
Improves lung function and decreases frequency of asthma exacerbations with regular use.
Lacks immediate bronchodilator effect; used for maintenance therapy in asthma.
Minimal systemic glucocorticoid activity due to extensive first-pass metabolism of swallowed drug fraction.
Does not treat acute bronchospasm or asthma attacks.
Exerts genomic effects by binding glucocorticoid receptors and altering gene expression.
Demonstrates favorable safety profile compared to systemic corticosteroids at therapeutic doses.
Breath-actuated inhaler improves drug delivery efficiency and patient compliance.
Can modulate immune response locally without significant systemic immunosuppression at recommended doses.

Therapeutic Or Clinical Uses

Maintenance treatment of asthma in adults and children aged 4 years and older.
Prevention of asthma exacerbations by controlling chronic airway inflammation.
Reduction of airway hyperresponsiveness associated with persistent asthma.
Adjunct therapy in asthma management to reduce need for systemic corticosteroids.
Control of symptoms in mild to moderate persistent asthma.
Use in patients requiring inhaled corticosteroids for long-term asthma control.
Off-label use in other inflammatory airway diseases upon physician discretion.
Not suitable for acute bronchospasm relief - requires concomitant rescue inhaler therapy.
Part of stepwise asthma management protocols recommended by major respiratory societies.
Improves overall lung function parameters such as FEV1 and peak expiratory flow rates.
Reduces airway remodeling and long-term irreversible damage in chronic asthma.
May be used in asthma patients with allergic components to reduce airway inflammation.
Helps in reducing asthma-related hospitalizations and emergency visits when used adequately.

Side Or Adverse Effects

Oropharyngeal candidiasis (yeast infection in the mouth) due to local immunosuppression.
Hoarseness, throat irritation, or cough following inhalation.
Sinus pain, nasal irritation, and upper respiratory tract symptoms such as nasal congestion.
Common cold-like symptoms including sneezing and sore throat.
Potential adrenal suppression with prolonged high-dose or systemic corticosteroid accumulation.
Rare allergic reactions including rash, hives, and facial swelling.
Growth suppression risk in pediatric patients with long-term use.
Blurred vision, tunnel vision, or eye pain indicating possible ocular side effects.
Worsening of asthma symptoms or paradoxical bronchospasm in rare cases.
Signs of infection including fever, chills, and body aches due to immunosuppression.
Weight gain, acne, increased body hair, and mood changes related to systemic corticosteroid effects.
Delayed wound healing and skin discoloration with prolonged exposure.
Adrenal insufficiency symptoms with abrupt discontinuation or high cumulative doses.
Potential risk of cataracts or glaucoma with chronic use.
Local mucosal irritation necessitating mouth rinsing after inhalation to reduce side effects.

Precautions

Do not use if allergic to beclomethasone or any component of the formulation.
Evaluate for underlying infections such as bacterial, fungal, or viral respiratory infections before initiating.
Use cautiously in patients with active or latent tuberculosis infection.
Monitor children for growth rate regularly during treatment.
Rinse mouth after inhalation to decrease risk of oral candidiasis.
Avoid abrupt discontinuation to prevent exacerbation of underlying asthma or adrenal insufficiency.
Use caution in patients with osteoporosis or low bone mineral density due to corticosteroid effects.
Monitor intraocular pressure in patients with risk factors for glaucoma or cataracts.
Avoid exposure to chickenpox or measles; seek medical advice promptly if exposed.
Be cautious in immunosuppressed patients or those receiving immunosuppressive therapy.
Pregnant or breastfeeding patients should use only if clearly needed and after risk-benefit assessment.
Inform patient on proper inhaler technique to ensure effective dosing and minimize side effects.
Assess for signs of worsening asthma symptoms or paradoxical bronchospasm regularly.
Adjust dose during periods of stress, illness, or surgery as per physician guidance.
Ensure patient uses concomitant rescue inhaler for acute asthma episodes.

Warnings

Qvar Redihaler is not a rescue medication and will not relieve acute asthma attacks.
Seek immediate medical attention if experiencing worsening breathing problems or asthma symptoms.
Risk of adrenal suppression with prolonged high-dose therapy or systemic exposure.
Potential development of oral thrush; implement mouth rinsing after each use.
Possible ocular effects including glaucoma and cataracts with long-term use.
Sudden discontinuation can worsen asthma control and precipitate adrenal crisis.
Increased susceptibility to infections including respiratory tract infections.
Monitor for signs of hypersensitivity reactions, which require drug discontinuation.
Avoid exposure to live vaccines during treatment due to immunosuppression risk.
Risk of slowed growth in pediatric patients; monitor height regularly.
Potential interactions with drugs metabolized by CYP3A4 increasing systemic corticosteroid effects.
Device canister may explode if exposed to excessive heat or open flame.
Do not puncture or burn the inhaler canister even if empty.
Use caution in patients with uncontrolled infections or systemic fungal infections.
Patients with glaucoma, cataracts, or increased intraocular pressure should be monitored closely.

Contraindication

Known hypersensitivity to beclomethasone dipropionate or any inhaler excipients.
Primary treatment of acute asthma attacks or status asthmaticus.
Patients with untreated systemic fungal infections.
Active respiratory infections where corticosteroid-induced immunosuppression may be harmful.
Hypersensitivity to milk proteins (depending on formulation constituents).
Persons unable to use the inhaler device effectively.
Severe hypersensitivity to other corticosteroids might indicate potential cross-reactivity.
Concomitant use with live vaccines due to immunosuppression.
Pregnancy and breastfeeding only if benefits outweigh risks; caution required.
Severe immunodeficiency states unless under specialist supervision.
Contraindicated where use might mask signs of infection progression without appropriate therapy.
Inability or unwillingness to adhere to chronic inhalation therapy regimen.
Use in children under 4 years of age due to lack of established safety and efficacy data.

Drug Interactions

Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may increase systemic corticosteroid exposure.
Other systemic corticosteroids can have additive effects increasing risk of adrenal suppression.
Concomitant use with immunosuppressive agents may enhance immunosuppression and infection risk.
Interaction with certain diuretics may potentiate hypokalemia during systemic corticosteroid use.
Possibility of reduced effectiveness if taken with drugs inducing CYP3A4 (e.g., rifampin, carbamazepine).
Concurrent use with non-potassium sparing diuretics should be monitored carefully.
May increase blood glucose levels; patients on antidiabetic agents should be monitored.
Drugs that affect electrolyte balance may require adjustment during corticosteroid therapy.
No significant interactions with common bronchodilators but monitor clinical response.
Co-administration with vaccines can result in diminished immune response.
Avoid live vaccines during treatment due to immunosuppression.
Interaction potential with herbal supplements metabolized by hepatic enzymes cannot be excluded.
Potential additive ocular side effects if used with other corticosteroid eye medications.
Alcohol and smoking may alter corticosteroid metabolism and effects.
Patients should inform healthcare providers of all medications to detect potential interactions.

Preparations Of The Drug

Qvar Redihaler pressurized metered-dose inhaler delivering beclomethasone dipropionate via breath-actuated technology.
Each inhaler device contains a specified number of metered inhalations with uniform dose delivery.
Available in dosages to provide 40 micrograms or 80 micrograms per actuation.
Formulated as a pressurized aerosol with hydrofluoroalkane (HFA) propellant free of chlorofluorocarbons (CFCs).
Device designed to eliminate need for coordination between inhaler actuation and inhalation.
Comes with a protective cap and dose counter for adherence monitoring.
Raw components include beclomethasone dipropionate, excipients compatible with inhalation delivery.
Packaging includes patient instructions on priming and cleaning the device.
No added lactose or gluten in many formulations, but patient-specific ingredient lists should be checked.
Manufactured according to GMP with stability supporting a room temperature shelf life until expiration.
Intended for maintenance therapy with no taste masking agents unlike oral formulations.
Should be stored away from heat, moisture, and direct sunlight to maintain integrity.
Disposal instructions emphasize not puncturing or incinerating inhaler canister.
No oral formulations included under the Qvar Redihaler brand; nebulized or oral corticosteroids are separate products.
Compatible with rinse water for cleaning but not chemical disinfectants.